Circassia's toleromune cat allergy treatment maintains symptom improvement two years after start of short-course therapy

摘要

CircassianLtd, a specialty biopharmaceutical company focused on allergychas announced the results of aphase II clinical, study, showing that a shortcourse of just four; doses: of its ToteroMone~R cat allergy.therapyvmaintained improvements in patients' symptoms two.yeqrs after the; start of treatment. The results were presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, USA on Sunday 24 February.